{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:00:08Z","timestamp":1760299208014},"reference-count":64,"publisher":"Informa UK Limited","issue":"18","funder":[{"name":"Millennium-Takeda, Roche and Celgene"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2015,9,30]]},"DOI":"10.2217\/fon.15.154","type":"journal-article","created":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T13:48:01Z","timestamp":1441633681000},"page":"2515-2524","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Alisertib in Treatment of Peripheral T-Cell Lymphomas"],"prefix":"10.1080","volume":"11","author":[{"given":"Eve","family":"Gallop-Evans","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, CF14 2TL, Wales, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,9,7]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.5611"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.5402\/2011\/623924"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu443"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr140"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.0188"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.1366"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp508"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10737"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27733"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7285"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06457.x"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.742521"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.4207"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12488"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.71"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S59269"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2434"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0015-z"},{"key":"e_1_3_3_28_1","unstructured":"RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas (RADCHOP). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01198665."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3389"},{"issue":"5","key":"e_1_3_3_30_1","first-page":"702","article-title":"Preliminary observations of a Phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani PL","year":"2005","unstructured":"Zinzani PL , AlinariL, TaniM, FinaM, PileriS, BaccaraniM. Preliminary observations of a Phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica90(5), 702\u2013703 (2005).","journal-title":"Haematologica"},{"key":"e_1_3_3_31_1","unstructured":"Alemtuzumab and CHOP in T-cell Lymphoma (ACT-1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00646854."},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.2456"},{"key":"e_1_3_3_35_1","unstructured":"ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01777152."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08298.x"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2010.02514.x"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.529204"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.816700"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.029"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29103"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/35048096"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.02364-06"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2658"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.7988"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.211"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.10.017"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0299"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2305-8"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.255"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.2174\/1872312807666131229122359"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.410"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0589"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0050-9"},{"key":"e_1_3_3_56_1","volume-title":"ASH Annual Meeting 2014","author":"Fanale MA","year":"2014","unstructured":"Fanale MA , HagemeisterFB, FayadLet al. A Phase I trial of alisertib plus romidepsin for relapsed\/refractory aggressive B- and T-cell lymphomas. Presented at: ASH Annual Meeting 2014. San Francisco, CA, USA, 6\u20139 December 2014 (Abstract 1744)."},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.5141.5141"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.8793"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.6327"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu339.42"},{"key":"e_1_3_3_61_1","unstructured":"Alisertib (MLN8237) or Investigator\u2019s Choice in Patients With Relapsed\/Refractory Peripheral T-Cell Lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01482962."},{"issue":"21","key":"e_1_3_3_62_1","first-page":"3683","article-title":"Integrated safety analysis of single-agent MLN8237 (alisertib), an investigational Aurora a kinase inhibitor, in patients with advanced hematologic malignancies and solid tumors","volume":"120","author":"Benaim E","year":"2012","unstructured":"Benaim E , ZhouX, LiuH, LeonardEJ, FreedlandE, NiculescuL. Integrated safety analysis of single-agent MLN8237 (alisertib), an investigational Aurora a kinase inhibitor, in patients with advanced hematologic malignancies and solid tumors. ASH Annual Meeting Abstracts120(21), 3683 (2012).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1536"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2190"},{"key":"e_1_3_3_65_1","unstructured":"MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab & Vincristine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01397825."},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095184"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.15.154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:42:35Z","timestamp":1719124955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.15.154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,7]]},"references-count":64,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2015,9,30]]}},"alternative-id":["10.2217\/fon.15.154"],"URL":"https:\/\/doi.org\/10.2217\/fon.15.154","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}